$1,150,000 of ABBOTT LABORATORIES lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"S.2003 The Strengthening Benefit Plans Act of 2025. Proposals related to The United States-Mexico-Canada Agreement (USMCA). Proposals related to tariffs on products imported into the United States. Proposals regarding US-China trade negotiations. Proposals related to data privacy/data collection, usage and retention. S.2426/H.R.3164 Equitable Community Access to Pharmacist Services Act. S.4118/H.R.7966 The Hospice Care Accountability, Reform and Enforcement Act of 2026. Proposals related to the advancement, testing and detection of Traumatic Brain Injury (TBI). Proposals related to Department of Defense coverage of continuous glucose monitors. Proposals related to digital health technologies and innovations. Proposals related to medical device cybersecurity. Proposals related to colorectal cancer screening. Proposals to support updates to the Veteran colorectal cancer screening directive. Proposals regarding the creation of quality measures for colorectal cancer screening. Proposals related to Medicare coverage of continuous glucose monitors. Proposals related to the National Coverage Determination for colorectal cancer screening. Proposals related to the competitive bidding process. Proposals related to The RAPID (Regulatory Alignment for Predictable and Immediate Device) coverage pathway initiative for eligible Breakthrough Medical Devices. Proposals related to U.S. global health programs and pandemic preparedness. Proposals related to third party litigation reform. S.3387 - Ensuring Safe and Toxic-Free Foods Act of 2023. H.R.2300 To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes. H.R.9817 Toxic Free Food Act of 2024. H.R.4958 The Grocery Reform and Safety (GRAS) Act. Proposals related to infant formula ingredients. Proposals related to access to infant formula. Proposals related to oral nutrition supplements usage in hospital care settings."
You can find more data on corporate lobbying on Quiver Quantitative.
ABT Congressional Stock Trading
Members of Congress have traded $ABT stock 11 times in the past 6 months. Of those trades, 5 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:
- REPRESENTATIVE RICK LARSEN sold up to $15,000 on 07/08.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 1 purchase worth up to $15,000 on 06/16 and 2 sales worth up to $30,000 on 05/15, 02/10.
- REPRESENTATIVE RICHARD MCCORMICK has traded it 3 times. They made 3 purchases worth up to $45,000 on 06/12, 03/19 and 0 sales.
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 05/27.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 05/12.
- REPRESENTATIVE RICK W. ALLEN sold up to $50,000 on 04/16.
- REPRESENTATIVE THOMAS H. KEAN, JR. purchased up to $15,000 on 01/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
ABT Insider Trading Activity
ABT insiders have traded $ABT stock on the open market 12 times in the past 6 months. Of those trades, 6 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:
- ROBERT B FORD (CHAIRMAN AND CEO) purchased 18,800 shares for an estimated $2,013,966
- DANIEL J STARKS has made 3 purchases buying 20,000 shares for an estimated $2,013,868 and 0 sales.
- PHILIP P BOUDREAU (EVP AND CFO) purchased 2,200 shares for an estimated $201,300
- JOHN G STRATTON purchased 2,000 shares for an estimated $173,640
- LOUIS H. MORRONE (EXECUTIVE VICE PRESIDENT) sold 1,144 shares for an estimated $132,223
- DANIEL GESUA SIVE SALVADORI (EVP AND GROUP PRESIDENT) sold 885 shares for an estimated $102,288
- ERIC SHROFF (Senior Vice President) sold 709 shares for an estimated $81,946
- MARY K MORELAND (EXECUTIVE VICE PRESIDENT) sold 613 shares for an estimated $70,850
- JOHN A. JR. MCCOY (VICE PRESIDENT AND CONTROLLER) sold 585 shares for an estimated $67,614
- ELIZABETH C. CUSHMAN (EVP, GC AND SECRETARY) sold 263 shares for an estimated $30,397
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ABT Hedge Fund Activity
We have seen 1,145 institutional investors add shares of ABT stock to their portfolio, and 1,623 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- J. STERN & CO. LLP removed 39,003,051 shares (-99.2%) from their portfolio in Q1 2026, for an estimated $3,959,199,707
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 32,310,527 shares (+245.0%) to their portfolio in Q1 2026, for an estimated $3,279,841,595
- CAPITAL INTERNATIONAL INVESTORS removed 25,731,218 shares (-40.7%) from their portfolio in Q1 2026, for an estimated $2,611,975,939
- FISHER ASSET MANAGEMENT, LLC removed 10,688,150 shares (-93.4%) from their portfolio in Q1 2026, for an estimated $1,084,954,106
- CAPITAL RESEARCH GLOBAL INVESTORS added 10,606,123 shares (+27.1%) to their portfolio in Q1 2026, for an estimated $1,076,627,545
- FRANKLIN RESOURCES INC added 8,867,817 shares (+79.5%) to their portfolio in Q1 2026, for an estimated $900,172,103
- CAPITAL WORLD INVESTORS removed 8,466,861 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $859,471,060
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ABT Analyst Ratings
Wall Street analysts have issued reports on $ABT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 02/02/2026
- BTIG issued a "Buy" rating on 01/23/2026
To track analyst ratings and price targets for ABT, check out Quiver Quantitative's $ABT forecast page.
ABT Price Targets
Multiple analysts have issued price targets for $ABT recently. We have seen 13 analysts offer price targets for $ABT in the last 6 months, with a median target of $121.0.
Here are some recent targets:
- Vijay Kumar from Evercore ISI Group set a target price of $112.0 on 07/06/2026
- David Rescott from Baird set a target price of $121.0 on 07/01/2026
- Adam Maeder from Piper Sandler set a target price of $115.0 on 06/22/2026
- Marie Thibault from BTIG set a target price of $131.0 on 04/27/2026
- Matt Miksic from Barclays set a target price of $143.0 on 04/20/2026
- Travis Steed from B of A Securities set a target price of $120.0 on 04/17/2026
- Suraj Kalia from Oppenheimer set a target price of $115.0 on 04/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
